Multiple sclerosis (MS) has long been regarded as a disease with different subtypes such as "relapsing" or "progressive." An international study, published on August 20, 2025, in Nature Medicine under ...

No treatment currently exists that can stop the silent progression of multiple sclerosis, and many promising drugs have proved ineffective in clinical trials. To reduce this failure rate and better ...

Secondary progressive multiple sclerosis (SPMS) is a chronic form of disease that occurs after relapsing-remitting MS, with a progressive disease course, and its pathogenesis remains unclear. CX3C ...

Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) caused by nerve inflammation that affects over 2 million people globally. Bromodomain and extra-terminal domain ...

To provide the right treatment for MS, it is important to know when the disease changes from relapsing-remitting to secondary progressive, a transition that is currently recognized on average three ...

The astroglia (a class of neural cells) of patients with MS overproduce a channel protein known as connexin 43. This overproduction facilitates the release of pro-inflammatory chemicals that trigger a ...

Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central ...

Clinicians and researchers have suspected for years that an aggressive, less-common form of multiple sclerosis (MS) is likely a distinct form of the disease. Now, new research conducted using a more ...